Abstract 6343: AnTenGagerTM, a novel “2+1” T cell engager platform, enables conditional T cell activation with reduced risk of CRS
Hou, Bing, Yuwen, Hui, Li, Tengteng, Ren, Yijing, Sun, Ao, Hu, Zaoshun, Mei, Jay, Shan, Bo
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 1032: Development of a novel companion diagnostic immunohistochemistry antibody for claudin 18.2-targeted therapies
Chen, Jishun, Bai, Suya, Bai, Yu, Hu, Zaoshun, Chen, Peng, Mei, Jay, Shan, Bo, Hou, Bing
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 2372: ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two nonoverlapping epitopes of LILRB4, for the treatment of monocytic AML
Sun, Ao, Gao, Mengshi, Guo, Rong, Liu, Huiling, Hu, Zaoshun, Zheng, Enlin, Yuwen, Hui, Chen, Peng, Mei, Jay, Shan, Bo, Hou, Bing
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article